Faricimab-svoa, a bispecific antibody indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration and diabetic macular oedema from Genentech was approved by the fda and by the European Medicines Agency in 2022 and is commercialized under the name of Vabysmo
- Vabysmo is a vascular endothelial growthfactor (VEGF) and angiopoietin-2 (Ang-2) inhibitor
- Vabysmo is for intravitreal injection.
Are you involved in R&D on antibodies ?
Are you planning to screen different #protein variants?
We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient proteinexpression in CHO cells and through personalized advices and consultancies.
